• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer

ww.care

Real Care for Wounded Warriors Foundation Inc.

  • Donate

Transcranial magnetic stimulation for posttraumatic stress disorder: an updated systematic review and meta-analysis.

April 27, 2016 05:03

Transcranial magnetic stimulation for posttraumatic stress disorder: an updated systematic review and meta-analysis.

Related Articles

Transcranial magnetic stimulation for posttraumatic stress disorder: an updated systematic review and meta-analysis.

Trends Psychiatry Psychother. 2016 Mar;38(1):50-5

Authors: Trevizol AP, Barros MD, Silva PO, Osuch E, Cordeiro Q, Shiozawa P

Abstract

Introduction Transcranial magnetic stimulation (TMS) is a promising non-pharmacological intervention for posttraumatic stress disorder (PTSD). However, randomized controlled trials (RCTs) and meta-analyses have reported mixed results. Objective To review articles that assess the efficacy of TMS in PTSD treatment. Methods A systematic review using MEDLINE and other databases to identify studies from the first RCT available up to September 2015. The primary outcome was based on PTSD scores (continuous variable). The main outcome was Hedges’ g. We used a random-effects model using the statistical packages for meta-analysis available in Stata 13 for Mac OSX. Heterogeneity was evaluated with I2 (> 35% for heterogeneity) and the χ2 test (p < 0.10 for heterogeneity). Publication bias was evaluated using a funnel plot. Meta-regression was performed using the random-effects model. Results Five RCTs (n = 118) were included. Active TMS was significantly superior to sham TMS for PTSD symptoms (Hedges’ g = 0.74; 95% confidence interval = 0.06-1.42). Heterogeneity was significant in our analysis (I2 = 71.4% and p = 0.01 for the χ2 test). The funnel plot shows that studies were evenly distributed, with just one study located marginally at the edge of the funnel and one study located out of the funnel. We found that exclusion of either study did not have a significant impact on the results. Meta-regression found no particular influence of any variable on the results. Conclusion Active TMS was superior to sham stimulation for amelioration of PTSD symptoms. Further RCTs with larger sample sizes are fundamental to clarify the precise impact of TMS in PTSD.

PMID: 27074341 [PubMed – in process]

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.

April 27, 2016 05:03

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.

http:--linkinghub.elsevier.com-ihub-imagRelated Articles

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.

Lancet Psychiatry. 2016 Apr 5;

Authors: Mithoefer MC, Grob CS, Brewerton TD

Abstract

4-phosphorloxy-N,N-dimethyltryptamine (psilocybin) and methylenedioxymethamfetamine (MDMA), best known for their illegal use as psychedelic drugs, are showing promise as therapeutics in a resurgence of clinical research during the past 10 years. Psilocybin is being tested for alcoholism, smoking cessation, and in patients with advanced cancer with anxiety. MDMA is showing encouraging results as a treatment for refractory post-traumatic stress disorder, social anxiety in autistic adults, and anxiety associated with a life-threatening illness. Both drugs are studied as adjuncts or catalysts to psychotherapy, rather than as stand-alone drug treatments. This model of drug-assisted psychotherapy is a possible alternative to existing pharmacological and psychological treatments in psychiatry. Further research is needed to fully assess the potential of these compounds in the management of these common disorders that are difficult to treat with existing methods.

PMID: 27067625 [PubMed – as supplied by publisher]

The burden of alcohol use disorders in U.S. Military veterans: results from the national health and resilience in veterans study.

April 27, 2016 05:02

The burden of alcohol use disorders in U.S. Military veterans: results from the national health and resilience in veterans study.

http:--media.wiley.com-assets-7315-19-WiRelated Articles

The burden of alcohol use disorders in U.S. Military veterans: results from the national health and resilience in veterans study.

Addiction. 2016 Apr 9;

Authors: Fuehrlein BS, Mota N, Arias AJ, Trevisan LA, Kachadourian LK, Krystal JH, Southwick SM, Pietrzak RH

Abstract

AIMS: To analyze data from a large, contemporary, nationally representative sample of U.S. veterans to evaluate: (1) the prevalence of lifetime alcohol use disorder (AUD), and past-year AUD; (2) common psychiatric comorbidities associated with lifetime AUD; and (3) correlates of lifetime and past-year probable AUD.

DESIGN: Data were analyzed from the National Health and Resilience in Veterans Study (NHRVS), a web-based survey of a random probability sample of a contemporary, nationally representative sample of U.S. military veterans.

SETTING: USA.

PARTICIPANTS: Nationally representative sample of 3,157 U.S. veterans aged 21 years and older.

MEASUREMENTS: Lifetime alcohol abuse and dependence were assessed according to DSM-IV diagnostic criteria using the Mini International Neuropsychiatric Interview, and combined into a single variable: AUD. Past-year probable AUD was assessed using the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C). Correlates of AUD, including psychiatric comorbidities, suicidality, and demographic characteristics, were also assessed.

FINDINGS: The prevalence of lifetime AUD and past-year probable AUD was 42.2% (95% confidence interval [CI] = 40.5%-43.9%), and 14.8% (95%CI = 13.6%-16.0%), respectively. Compared with veterans without AUD, those with lifetime AUD had substantially elevated rates of lifetime and current mood and anxiety disorders (odds ratios [ORs] = 2.6-4.1), drug use disorder (OR = 10.7), lifetime suicide attempt (OR = 4.1) and current suicidal ideation (OR = 2.1). Younger age, male sex, lower education, lower annual household income, and greater number of lifetime traumatic events were independently associated with lifetime AUD. Younger age, male sex, unpartnered marital status, and a lifetime diagnosis of major depressive disorder were independently associated with past-year probable AUD.

CONCLUSIONS: More than 40% of U.S. military veterans have a lifetime history of alcohol use disorder (AUD). Veterans with a lifetime history of AUD have substantial comorbid psychiatric burden, including elevated rates of suicidal ideation and attempts. Certain sociodemographic (e.g., younger age, male sex, lower education) and clinical (e.g., trauma burden, history of depression) characteristics are associated with increased risk of AUD.

PMID: 27061707 [PubMed – as supplied by publisher]

Receptivity to Alcohol-Related Care among US Women Veterans with Alcohol Misuse.

April 27, 2016 02:36

Receptivity to Alcohol-Related Care among US Women Veterans with Alcohol Misuse.

Related Articles

Receptivity to Alcohol-Related Care among US Women Veterans with Alcohol Misuse.

J Addict Dis. 2016 Apr 6;:0

Authors: Lewis ET, Jamison AL, Ghaus S, Durazo EM, Frayne SM, Hoggatt KJ, Bean-Mayberry B, Timko C, Cucciare MA

Abstract

BACKGROUND: Previous research indicates women Veterans have a potentially large, unmet need for alcohol-related care but are under-represented in treatment settings.

OBJECTIVE: This study’s purpose was to identify factors associated with women Veterans’ receptivity to a recommendation for alcohol-related care when they present to Veterans Affairs (VA) primary care with alcohol misuse.

METHODS: Semi-structured interviews were conducted in 2012-2013 with 30 women Veterans at two VA facilities who screened positive for alcohol misuse during a primary care visit and discussed their alcohol use with their primary care provider. Qualitative analyses identified nine themes women used to describe what affected their receptivity to a recommendation for alcohol-related care (i.e., VA specialty substance use disorder services).

RESULTS: The most common themes positively associated with women’s receptivity included self-appraisal of their drinking behavior as more severe; the provider’s presentation of treatment options; availability of gender-specific services; and worse physical and mental health.

DISCUSSION: The themes identified here may have important implications for the clinical strategies providers can use to present alcohol-related care options to women Veterans to facilitate their use of care. These strategies include educating women about the health effects of alcohol misuse and increasing providers’ knowledge about available care options (within the care organization or the community), including the availability of gender-specific services.

PMID: 27049338 [PubMed – as supplied by publisher]

Late-life exacerbation of PTSD symptoms in US veterans: results from the National Health and Resilience in Veterans Study.

April 27, 2016 02:36

Late-life exacerbation of PTSD symptoms in US veterans: results from the National Health and Resilience in Veterans Study.

Related Articles

Late-life exacerbation of PTSD symptoms in US veterans: results from the National Health and Resilience in Veterans Study.

J Clin Psychiatry. 2016 Mar;77(3):348-54

Authors: Mota N, Tsai J, Kirwin PD, Harpaz-Rotem I, Krystal JH, Southwick SM, Pietrzak RH

Abstract

OBJECTIVE: More than 60% of US military veterans are 55 years or older. Although several case studies have suggested that older age is associated with a higher likelihood of reactivated or delayed-onset posttraumatic stress disorder (PTSD) symptoms in veterans, population-based data on the prevalence and determinants of this phenomenon are lacking.

METHOD: Using data from the National Health and Resilience in Veterans Study (NHRVS: Wave 1 = October 2011-December 2011; Wave 2 = September 2013), a nationally representative, cohort study of US veterans, we evaluated the prevalence and determinants of exacerbated PTSD symptoms in 1,441 veterans 55 years or older using a DSM-IV-based measure in 2011 and a DSM-5-based measure in 2013. Veterans whose worst trauma occurred at least 5 years prior to Wave 2 of the NHRVS (mean = 28.6 years) and who reported a clinically significant increase (ie, ≥ 0.5 standard deviation [SD]; mean = 1.27, SD = 0.78) in PTSD symptoms from Wave 1 (lifetime) to Wave 2 (past-month) were identified as having exacerbated PTSD symptoms.

RESULTS: Results revealed that 9.9% of older US veterans experienced exacerbated PTSD symptoms an average of nearly 3 decades after their worst trauma. A multivariable logistic regression model indicated that greater self-reported cognitive difficulties at Wave 1 independently predicted exacerbated PTSD symptoms at Wave 2. Post hoc analysis revealed that this association was driven by greater severity of executive dysfunction (adjusted odds ratio range, 1.27-3.22).

CONCLUSIONS: Approximately 1 in 10 older US veterans experiences a clinically significant exacerbation of PTSD symptoms in late life. Executive dysfunction may contribute to risk for exacerbated PTSD symptoms. These results suggest that exacerbated PTSD symptoms are prevalent in US veterans and highlight potential targets for identifying veterans at risk for this phenomenon.

PMID: 27046308 [PubMed – in process]

Observational evidence for buprenorphine’s impact on posttraumatic stress symptoms in veterans with chronic pain and opioid use disorder.

April 27, 2016 02:36

Observational evidence for buprenorphine’s impact on posttraumatic stress symptoms in veterans with chronic pain and opioid use disorder.

Related Articles

Observational evidence for buprenorphine’s impact on posttraumatic stress symptoms in veterans with chronic pain and opioid use disorder.

J Clin Psychiatry. 2016 Mar 1;

Authors: Seal KH, Maguen S, Bertenthal D, Batki SL, Striebel J, Stein MB, Madden E, Neylan TC

Abstract

OBJECTIVE: Posttraumatic stress disorder (PTSD), chronic pain, and substance use disorders are prevalent co-occurring conditions that are challenging to treat individually, and there is no evidence-based treatment for all 3. Buprenorphine, used to treat opioid use disorder and chronic pain, is a partial nociceptin opioid receptor agonist. In preclinical studies, a nociceptin opioid receptor agonist was shown to mitigate PTSD symptoms in acute trauma. We compared buprenorphine to other opioid medications in its impact on PTSD symptoms in patients with chronic pain and opioid and/or other substance use disorders.

METHOD: We assembled a retrospective cohort of 382 Iraq and Afghanistan veterans in US Department of Veterans Affairs health care from October 1, 2007, to July 29, 2013, with ICD-9-CM diagnoses of PTSD, chronic pain, and substance use disorders. We used time-varying general estimating equation models to assess the primary outcome, which was change in PTSD symptoms (measured using the PTSD Checklist and the Primary Care PTSD Screen) among veterans initiated on sublingual buprenorphine versus those maintained on moderately high-dose opioid therapy.

RESULTS: Twice as many veterans in the buprenorphine group (23.7%) compared to those in the opioid therapy group (11.7%) experienced improvement in PTSD symptoms (P = .001). Compared to veterans in the opioid therapy group, veterans receiving buprenorphine showed significant improvement in PTSD symptoms after 8 months, with increasing improvement up to 24 months (incidence rate ratio = 1.79; 95% CI, 1.16-2.77; P = .009). There were no differences in the longitudinal course of pain ratings between groups.

CONCLUSIONS: This observational study is the first to report an incidental effect of buprenorphine compared to opioid therapy in improving PTSD symptoms in veterans.

PMID: 27035058 [PubMed – as supplied by publisher]

Neurology in the Vietnam War.

April 27, 2016 02:36

Neurology in the Vietnam War.

Related Articles

Neurology in the Vietnam War.

Front Neurol Neurosci. 2016 Apr 1;38:201-213

Authors: Gunderson CH, Daroff RB

Abstract

Between December 1965 and December 1971, the United States maintained armed forces in Vietnam never less than 180,000 men and women in support of the war. At one time, this commitment exceeded half a million soldiers, sailors, and airmen from both the United States and its allies. Such forces required an extensive medical presence, including 19 neurologists. All but two of the neurologists had been drafted for a 2-year tour of duty after deferment for residency training. They were assigned to Vietnam for one of those 2 years in two Army Medical Units and one Air Force facility providing neurological care for American and allied forces, as well as many civilians. Their practice included exposure to unfamiliar disorders including cerebral malaria, Japanese B encephalitis, sleep deprivation seizures, and toxic encephalitis caused by injection or inhalation of C-4 explosive. They and neurologists at facilities in the United States published studies on all of these entities both during and after the war. These publications spawned the Defense and Veterans Head Injury Study, which was conceived during the Korean War and continues today as the Defense and Veterans Head Injury Center. It initially focused on post-traumatic epilepsy and later on all effects of brain injury. The Agent Orange controversy arose after the war; during the war, it was not perceived as a threat by medical personnel. Although soldiers in previous wars had developed serious psychological impairments, post-traumatic stress disorder was formally recognized in the servicemen returning from Vietnam.

PMID: 27035455 [PubMed – as supplied by publisher]

Validity testing and neuropsychology practice in the VA healthcare system: results from recent practitioner survey.

April 27, 2016 02:36

Validity testing and neuropsychology practice in the VA healthcare system: results from recent practitioner survey.

Related Articles

Validity testing and neuropsychology practice in the VA healthcare system: results from recent practitioner survey.

Clin Neuropsychol. 2016 Apr 1;:1-18

Authors: Young JC, Roper BL, Arentsen TJ

Abstract

OBJECTIVE: A survey of neuropsychologists in the Veterans Health Administration examined symptom/performance validity test (SPVT) practices and estimated base rates for patient response bias.

METHOD: Invitations were emailed to 387 psychologists employed within the Veterans Affairs (VA), identified as likely practicing neuropsychologists, resulting in 172 respondents (44.4% response rate). Practice areas varied, with 72% at least partially practicing in general neuropsychology clinics and 43% conducting VA disability exams.

RESULTS: Mean estimated failure rates were 23.0% for clinical outpatient, 12.9% for inpatient, and 39.4% for disability exams. Failure rates were the highest for mTBI and PTSD referrals. Failure rates were positively correlated with the number of cases seen and frequency and number of SPVT use. Respondents disagreed regarding whether one (45%) or two (47%) failures are required to establish patient response bias, with those administering more measures employing the more stringent criterion. Frequency of the use of specific SPVTs is reported.

CONCLUSIONS: Base rate estimates for SPVT failure in VA disability exams are comparable to those in other medicolegal settings. However, failure in routine clinical exams is much higher in the VA than in other settings, possibly reflecting the hybrid nature of the VA’s role in both healthcare and disability determination. Generally speaking, VA neuropsychologists use SPVTs frequently and eschew pejorative terms to describe their failure. Practitioners who require only one SPVT failure to establish response bias may overclassify patients. Those who use few or no SPVTs may fail to identify response bias. Additional clinical and theoretical implications are discussed.

PMID: 27032437 [PubMed – as supplied by publisher]

  • « Previous Page
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Next Page »

Categories

  • PTSD
  • PTSD Community
  • PTSD Science
  • PTSD Treatment Cure Causes
  • Veterans PTSD

Archives

  • June 2016
  • May 2016
  • April 2016
  • About
  • For Scientists
  • Contact Us

2016-2021 Real Care for Wounded Warriors, A 501(c)3 organization. All donations are tax deductible.